Mereo BioPharma Group plc (MREO)

0.4367 +0.0467 (+11.97%) At close: 04:00PM EDT

Mereo BioPharma Group plc

1 Cavendish Place
4th Floor
London W1G 0QF
United Kingdom
44 33 3023 7300
https://www.mereobiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 38

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Denise Scots-Knight Ph.D.	Co-Founder, CEO & Exec. Director	1.17M	N/A	1959
Mr. Charles Sermon	Co-Founder, Gen. Counsel & Company Sec.	855.93k	N/A	1969
Dr. Alastair MacKinnon M.D., MBBS	Co-Founder and Chief of Portfolio & Pipeline Strategy	843.43k	N/A	1970
Dr. John P. Richard M.B.A., MBA	Co-Founder & Chief Bus. Officer	799.48k	N/A	1957
Dr. John A. Lewicki Ph.D.	Chief Scientific Officer	756.02k	N/A	1952
Ms. Alexandra Hughes-Wilson	Chief of Patient Access & Commercial Planning	484.37k	N/A	1971
Ms. Christine Fox CPA	Chief Financial Officer	N/A	N/A	1981
Dr. Fiona Bor	Head of Intellectual Property	N/A	N/A	N/A
Dr. Jackie Parkin	Therapy Area Head of Respiratory Endocrinology	N/A	N/A	N/A
Dr. Arun Mistry	Therapeutic Area Head of Setrusumab	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Corporate governance

Mereo BioPharma Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.